Founded Year

2016

Stage

Series C - II | Alive

Total Raised

$115.31M

Last Raised

$33M | 2 yrs ago

About Vineti

Vineti is a commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for personalized therapies. The Vineti software solution aligns and orchestrates the cell and gene therapy process and improve product performance overall. The Vineti platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic therapies. The platform can also be harnessed for drug products requiring companion diagnostics or REMS programs.

Vineti Headquarter Location

633 Howard St.

San Francisco, California, 94105,

United States

(415) 704-8730

Vineti's Product Videos

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Vineti's Products & Differentiation

See Vineti's products and how their products differentiate from alternatives and competitors

  • Personalized Therapy Management (PTM) Enterprise

    PTM Enterprise™ drives the advanced therapy patient journey, from autologous and allogeneic cell and gene therapies to personalized cancer vaccines, from clinical trials through commercialization. Personalized therapeutics have the potential to transform lives. But as a promising product scales and approaches commercialization, advanced therapy innovators face significant obstacles in getting treatments to the patients who need them: Your enabling technology may lag behind your science Your existing software systems may not be integrated with each other, and they don’t scale Complex regulatory and compliance processes threaten to slow your project with document and data management challenges and potential regulatory delays Uneven ongoing data management keeps COGS very high

    Differentiation

    PTM Enterprise™ is the proven end-to-end digital solution purpose-built to meet the unique demands of the growing personalized therapeutics industry. With a seamless user experience, PTM Enterprise™… 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Vineti

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Vineti in 5 CB Insights research briefs, most recently on Oct 30, 2020.

Expert Collections containing Vineti

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vineti is included in 4 Expert Collections, including Digital Health 150.

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

D

Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Vineti Patents

Vineti has filed 3 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/29/2019

5/3/2022

Clusters of differentiation, Transcription factors, Immune system, Immunology, Privacy

Grant

Application Date

12/29/2019

Grant Date

5/3/2022

Title

Related Topics

Clusters of differentiation, Transcription factors, Immune system, Immunology, Privacy

Status

Grant

Latest Vineti News

In Armenia’s biotech boom, remarkable women are leading the way

May 30, 2022

By LARA SETRAKIAN 8 minute Read A star entrepreneur in Armenia, Marina Aghayan is an embodiment of her country’s ambitions in biotechnology—and a reflection of its grit. From her hometown of Yerevan she went as a graduate student to Spain, subsisting on a food budget of 3 euros a month. advertisement advertisement “I found a place to buy bread with 25 slices for 33 cents,” Aghayan tells me. “I found out that when you cook rice—80 cents for 1 kilogram—you triple the size and the mass of the rice. So it’s really very nice to use when you’re suffering.” Quickly learning to overcome hunger and adversity, she began publishing prolifically in the field of materials science and went on to earn a PhD in Estonia. Last year her journey came full circle: She returned to Armenia and founded AIP Scientific , a bioengineering firm that produces customized orthopedic implants. The company uses 3D printing and biodegradable materials that promote new bone growth. Aghayan is also cofounder and CEO of Fact Industries , a bio- and material engineering company in Estonia that develops 3D-printing prototypes for the European Space Agency. I met Aghayan a few months after I moved to Armenia with my family. It was an early-pandemic lifestyle move: My husband and I, born in the U.S. and Canada, respectively, both grew up in ethnic Armenian households. We thought it would be a great experience for us and our kids to weather the lockdowns in Yerevan while absorbing the culture and language plus roaming the mountains and monasteries in the countryside. What we didn’t anticipate was meeting entrepreneurs like Marina Aghayan, who stunned us with their passion, perseverance, and potential, and quickly turned us into angel investors in this country. advertisement advertisement Aghayan is part of the vanguard of biotech entrepreneurs aiming to build a production hub for niche products, innovative software, and mathematical models in Armenia. In the quietly emerging ecosystem of companies and educational initiatives, many of the standout founders are women like her, representing a blend of technical skill and exceptional determination. According to the Armenian Bioinformatics Institute, 60% to 70% of professionals in biotech are women (compared to an estimated 47% in biotech companies worldwide ). And they are positioning Armenia’s biotech sector for growth. Those women founders are among the reasons I am convinced that Armenia is a prime destination for global tech investors and impact accelerators. Their stories and the sector opportunities they’re creating are too compelling to miss—a classic case of underinvestment in women and in emerging market technology clusters. Despite the strong foundation and meaningful openings for the Armenian biotech industry, biotech startups here attracted roughly $50 million in venture capital investment in 2021, a fraction of the $3.6 billion invested in the sector globally. Given the talent and opportunity in this country, more investors and impact funds should include Armenian ventures in their pipelines. They’d be in good company: Earlier this year Nvidia, a global high-tech giant with a significant AI and machine learning portfolio, opened a research center in Yerevan. “There are a lot of great brains over here that can contribute to what we’re building,” Lev Lebaredian, a VP at Nvidia, said in a local media interview. advertisement Armen Kherlopian, cofounder of BAJ Accelerator, which supports Armenian biotech firms, was also driven to invest after seeing strengths in human capital and talent development. “I think it’s something in the educational system. The women are excelling,” Kherlopian says. A native of New Jersey, he completed his PhD in biophysics with a focus on machine learning at the Weill Cornell Graduate School of Medical Sciences. “The mathematical prowess you see here is now making its way into biotech,” Kherlopian observed from his new home in Yerevan. As one central example, he noted that in Armenia, “computational drug design, building medicines by computer, is making major strides.” Jack Topdjian, a partner at Healthcare Equity Angels, a syndicated healthcare and biotech investment firm in Miami, says that something big is happening here. It compelled him to invest in the country and begin advising startups, looking for areas where the small landlocked country can excel. advertisement “Several AI applications in biotechnology, personalized medicine, genomics, and agriculture are already making their way from the labs and early-stage companies to global markets,” he says. “The two areas that impressed me are the acceleration of R&D and precision medicine. It’s the combination of deep computational science across artificial intelligence, machine learning, advanced visualization, and quantum computing along with a deep expertise in medicine, biotechnology, and genomics fields,” Topdjian says. “You need these complex sciences working in tandem to make big breakthroughs happen.” By leaning into that intersection he sees what he considers Armenia’s homegrown advantages: Its deep pool of human talent, relevant fields of advanced education, cost advantage, and diaspora connections to major research centers across the world. He predicts venture investment in the country could double by next year. Enter Roza Bejanyan, another female founder leading her country’s biotech surge. Her company, Medpoint Technologies , is building tools for earlier and more precise diagnosis of diseases including pediatric cancer, brain cancer, and lung cancer using digital pathology: AI algorithms applied to analyzing clinical samples. One of the company’s products is a bloodless, noninvasive AI-powered test based on nanostructures for early-stage lung cancer and respiratory diseases. advertisement From her base in Yerevan, Bejanyan leveraged some powerful advantages in building her algorithms—foremost, a trove of biomedical data that was easier to access than in other countries. “In post-Soviet countries medical data is more centralized,” she says. “As long as the patient has agreed you can use their data.” The second advantage was a deep pool of talent, specifically in the form of the well-trained pathologists who could collaborate with biotech startups. The presence of specialized pathologists in Armenia and surrounding countries has helped Bejanyan move forward faster with product development. “Data annotation was ​the most critical limitation in having the kind of data we need to train our AI model,” she says. “We need whole slide images of a biopsy, annotated and classified by a pathologist. . . . It’s impossible to generate a big amount of data without these advising pathologists.” She is now turning those doctors into a product unto themselves, building a platform for pathologists in the region who can annotate biomedical data for tech companies around the world. The digital delivery of products and processes also makes it easier to form joint ventures: Denovo Sciences , an early-stage biotech company in Armenia, is collaborating with Emory University to codevelop therapies for hepatitis B and with the University of California, San Diego, to do the same for hepatitis C. advertisement Denovo uses AI to accelerate drug discovery. Irina Tirosyan, the company’s lead data scientist, is also a lecturer at the American University of Armenia, educating the next generation of specialists in her field. That is part of a unified strategy, led by Tirosyan and others at her company, to create a cadre of future hires and colleagues. “There’s a good talent pool when it comes to AI and data science, but it’s hard to find people at the crossroads of natural sciences and AI. We create our own talent acquisition pipeline,” Tirosyan says. Denovo started Cheminformatics Bootcamp to accelerate the process, teaching participants computational chemistry and data science for drug discovery. As the biotech ecosystem has grown, global technology firms have started to take advantage of Armenia’s talent pool. Vineti , a San Francisco-based company that produces enterprise software to manage personalized therapeutics, built a team of 60 people in Yerevan. That office handles engineering, product, and support, as well as human resources and administrative functions. advertisement “Having a strong team in Armenia gives us significant advantages,” says Ann Klein, Vineti’s CEO. “Our Armenia team is an important part of working with our customers in Europe and Asia. Their perspective helps us understand our customers worldwide.” She has set up her Yerevan office in part to serve the relatively close Middle East and Indian markets. “Armenia is a perfect hub to serve all those regions with significant cost efficiencies compared to the U.S. and Europe,” Klein adds. The limitations of working in Armenia are like cliffs that the ecosystem is working to scale. As the founding director of the Armenian Bioinformatics Institute , Lilit Nersisyan and her colleagues are pulling together the labs and expensive machinery required to train Armenia’s next generation. advertisement “We are still behind in terms of genomics infrastructure development,” Nersisyan says. The upshot: staying focused, for now, on the less equipment-intensive areas of data analysis and the benefit of a small, tight-knit ecosystem where interactions are easy and frequent. “We can [easily] collaborate across fields and find solutions to whatever problem is in front of us,” she says. “We can have a niche as an interdisciplinary workforce.” Topdjian, the investor in Miami, says the key for Armenia is to develop specialized subfields of expertise, areas that leverage deep science to add value to the global health and biotech industry. This would track the role Armenia used to play before the fall of the Soviet Union, when it manufactured high-tech components for the wider country’s mechanical engineering and aviation industries and invented some of the world’s earliest computers. advertisement Aram Salatian helped establish the Museum of Science and Technology in 2008, part of Yerevan’s Engineering City, to capture that history of research and innovation. “Our natural calling is to be a place for difficult and complex problems, problems that are not easy to be solved by the average specialist,” he says. “It’s the role that we historically and existentially have had to play.” Reflecting on that track record helps motivate a new generation of science and mathematics brains in this small country. They are approaching the future with the confidence to take on the thorny, complex problems of their field; above all, the women founders I have met embody that grit and perseverance around a unique set of obstacles. With the inner drive and few crafty work-arounds, they are bent on creating things of high quality that appeal to the global field of health-tech investors. That is an attitude and approach worth betting on. Lara Setrakian is a journalist and impact investor based in Yerevan, Armenia. She is an Impact Partner with Fresco Capital, a global venture capital firm. She is on Twitter @lara . advertisement

Vineti Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Vineti Rank

  • When was Vineti founded?

    Vineti was founded in 2016.

  • Where is Vineti's headquarters?

    Vineti's headquarters is located at 633 Howard St., San Francisco.

  • What is Vineti's latest funding round?

    Vineti's latest funding round is Series C - II.

  • How much did Vineti raise?

    Vineti raised a total of $115.31M.

  • Who are the investors of Vineti?

    Investors of Vineti include Threshold Ventures, Section 32, Canaan Partners, GE Ventures, dRx Capital and 10 more.

  • Who are Vineti's competitors?

    Competitors of Vineti include TrakCel.

  • What products does Vineti offer?

    Vineti's products include Personalized Therapy Management (PTM) Enterprise and 1 more.

You May Also Like

TrakCel Logo
TrakCel

TrakCel's cell, gene, and immunotherapy management solution improves clinical study efficacy and accelerates global scale-up and scale-out by implementing communications technology to integrate the delivery path from needle-to-needle. The technology provides interactive instructions to professionals across the supply chain and gives stakeholders on-demand visibility of procedural results and chain-of-custody data for immediate trace-ability, validation, and compliance audits.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.